[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531169":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":23,"centralContacts":27,"locations":36,"responsibleParty":58,"collaborators":11,"id":60,"slug":61,"hasResults":62,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":11,"eligibilityCriteria":66,"healthyVolunteers":62,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":84,"overallStatus":39,"whyStopped":11,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"Second Affiliated Hospital of Guangzhou Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"γδT cell therapy for solid tumor","EXPERIMENTAL",null,[13],"Biological: Cell therapy for solid tumors",{"label":15,"type":10,"description":11,"interventionNames":16},"CAR-γδT cell therapy for solid tumor",[13],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"BIOLOGICAL","Cell therapy for solid tumors","Transfer γδT cells into patients for anti-ancer therapy.",[15,9],[24],{"name":25,"affiliation":5,"role":26},"Zhenfeng Zhang, MD, PhD","PRINCIPAL_INVESTIGATOR",[28,32],{"name":25,"role":29,"phone":30,"phoneExt":11,"email":31},"CONTACT","0086-020-39195965","zhangzhf@gzhmu.edu.cn",{"name":33,"role":29,"phone":34,"phoneExt":11,"email":35},"Bingjia He, MD","+862039195965","464677938@qq.com",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"The Second Affiliated Hospital of Guangzhou Medical University","RECRUITING","Guangzhou","Guangdong","510260","China","CN",{"type":46,"coordinates":47},"Point",[48,49],113.25,23.11667,{"lat":49,"lon":48},[52,54],{"name":53,"role":29,"phone":11,"phoneExt":11,"email":31},"Zhenfeng Zhang, MD,PhD",{"name":55,"role":29,"phone":56,"phoneExt":11,"email":57},"Deji Chen, MD,PhD","+86-020-34153532","chendeji2003@163.com",{"type":59,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100531169","phase-1-gpc3mesothelin-car-t-cells-against-cancers-100531169",false,"NCT06196294","GPC3\u002FMesothelin-CAR-γδT Cells Against Cancers","GPC3\u002FMesothelin Targeted CAR-γδT for Immunotherapy of Solid Cancer: Phase I Clinical Trial","Inclusion Criteria:\n\n1\\. Patients with advanced cancer that expresses GPC3 or Mesothelin protein; 2. Life expectancy \\>12 weeks; 3. Adequate heart, lung, liver, kidney, and blood function; 4. Available autologous transduced T cells with greater than or equal to 20% expression of GPC3\u002FMesothelin-CAR determined by flow-cytometry and killing of Mesothelin-positive targets greater than or equal to 20% in cytotoxicity assay; 5. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\n\\-\n\nExclusion Criteria:\n\n1. Had accepted gene therapy before;\n2. Severe virus infection such as HBV, HCV, HIV, et al;\n3. Known HIV positivity;\n4. Active infectious disease related to bacteria, virus,fungi,et al;\n5. Other severe diseases that the investigators consider not appropriate;\n6. Pregnant or lactating women;\n7. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent\u002Fkg\u002Fday);\n8. Other conditions that the investigators consider not appropriate. -","ALL","18 Years","75 Years",{"count":71,"type":72},30,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","The third generation of GPC3\u002Fmesothelin targeted CAR-γδT cells have been constructed and their anti-cancer function has been verified by multiple in vitro and in vivo studies. Clinical studies will be performed to test anti-cancer function of the CAR-γδT cells for immunotherapy of human cancer patients with GPC3 or Mesothelin expressions. In this phase I study, the safety, tolerance, and preliminary efficacy of the GPC3\u002FMesothelin-CAR-γδT cell immunotherapy on human cancers will firstly be evaluated.",[78,79,80,81,82,83],"Pancreas Cancer","Lung Cancer","Liver Cancer","Mesothelioma","CAR-T Cell Therapy","Solid Tumor, Adult",[85,86,87,88,89],"Solid Tumor","CAR-γδT","γδT","GPC3","Mesothelin","2024-06-22",{"date":92,"type":93},"2024-06-26","ACTUAL",{"date":95,"type":93},"2024-05-10",{"date":97,"type":72},"2036-12-30",{"name":5,"class":6},1]